LPL Financial LLC Buys 925 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

LPL Financial LLC raised its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 6.7% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 14,710 shares of the biopharmaceutical company’s stock after acquiring an additional 925 shares during the quarter. LPL Financial LLC’s holdings in Alnylam Pharmaceuticals were worth $2,947,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Nordea Investment Management AB grew its position in shares of Alnylam Pharmaceuticals by 1.1% in the 1st quarter. Nordea Investment Management AB now owns 8,643 shares of the biopharmaceutical company’s stock valued at $1,714,000 after acquiring an additional 96 shares during the period. abrdn plc increased its position in Alnylam Pharmaceuticals by 7.5% in the 4th quarter. abrdn plc now owns 13,124 shares of the biopharmaceutical company’s stock valued at $3,119,000 after acquiring an additional 915 shares during the period. Connor Clark & Lunn Investment Management Ltd. boosted its stake in Alnylam Pharmaceuticals by 940.4% during the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 12,901 shares of the biopharmaceutical company’s stock worth $2,584,000 after acquiring an additional 11,661 shares in the last quarter. Amalgamated Bank raised its holdings in Alnylam Pharmaceuticals by 1.5% during the first quarter. Amalgamated Bank now owns 14,078 shares of the biopharmaceutical company’s stock worth $2,820,000 after buying an additional 211 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC raised its holdings in shares of Alnylam Pharmaceuticals by 12.4% in the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 6,592 shares of the biopharmaceutical company’s stock valued at $1,567,000 after purchasing an additional 726 shares during the last quarter. 93.98% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals Trading Down 0.4 %

Shares of ALNY stock opened at $200.34 on Wednesday. The company has a market cap of $25.04 billion, a PE ratio of -23.27 and a beta of 0.45. Alnylam Pharmaceuticals, Inc. has a 12-month low of $178.64 and a 12-month high of $242.97. The business’s fifty day simple moving average is $193.00 and its 200-day simple moving average is $195.45.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($2.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.72) by ($0.49). The company had revenue of $318.75 million for the quarter, compared to analyst estimates of $331.73 million. Alnylam Pharmaceuticals had a negative net margin of 85.95% and a negative return on equity of 1,287.80%. On average, equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -6.71 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Royal Bank of Canada reiterated an “outperform” rating and set a $270.00 target price on shares of Alnylam Pharmaceuticals in a research report on Monday, August 28th. William Blair restated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Tuesday, July 25th. HC Wainwright restated a “buy” rating and issued a $405.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday, August 7th. StockNews.com initiated coverage on shares of Alnylam Pharmaceuticals in a research report on Thursday, August 17th. They set a “hold” rating for the company. Finally, Citigroup lifted their price target on shares of Alnylam Pharmaceuticals from $265.00 to $266.00 and gave the stock a “buy” rating in a research note on Friday, August 4th. Six research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $247.79.

Insiders Place Their Bets

In other news, CEO Yvonne Greenstreet sold 4,057 shares of the business’s stock in a transaction dated Friday, August 4th. The shares were sold at an average price of $185.85, for a total transaction of $753,993.45. Following the completion of the sale, the chief executive officer now owns 35,216 shares of the company’s stock, valued at $6,544,893.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 4,166 shares of the stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $183.89, for a total value of $766,085.74. Following the sale, the chief marketing officer now directly owns 4,345 shares of the company’s stock, valued at approximately $799,002.05. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Yvonne Greenstreet sold 4,057 shares of the stock in a transaction that occurred on Friday, August 4th. The shares were sold at an average price of $185.85, for a total transaction of $753,993.45. Following the completion of the sale, the chief executive officer now directly owns 35,216 shares in the company, valued at $6,544,893.60. The disclosure for this sale can be found here. Over the last quarter, insiders sold 15,144 shares of company stock worth $2,806,347. Company insiders own 1.40% of the company’s stock.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.